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patency over the course of the study. The 56 thread devices were well tolerated locally
and yielded fewer signs of inﬂammation and neointimal hyperplasia. Further pre-
clinical and clinical studies will extend assessment of the long-term safety and
effectiveness of the MFM.
TCT-440
Further Evolution In Aortic Arch Endografting
Sagi Raz1, Marcel Goodman2, Daniel Silverberg3, David Planer4
1Endospan, Hertzelia, Israel, 2University of Western Australia, Perth, Australia, 3The
Chaim Sheba Medical Center, Tel Hashomer, Israel, 4Hebrew University-Hadassah
Medical Center, Jerusalem, Israel
Background: Conventional surgical or hybrid repair of aortic arch aneurysms carries
substantial risk of mortality and morbidity. Early experience with custom made
branched arch endografts showed promising results, although availability and pro-
duction time limit their widespread use. Consequently, many patients remain
untreated.This preclinical study is the ﬁrst report of an off-the-shelf modular aortic
arch endograft, with a novel Z shape design addresses the unique procedural and long
term challenges with complete endovascular therapy for aortic arch pathologies.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/NeMethods: Sixteen pigs (7 acute, 9 chronic) underwent endovascular implantation of
the Nexus arch endograft over a brachio-iliac through & through wire technique,
with modular extensions to ascending aorta and LCC. Aggregate follow-up period was
481 days.
Results: Successful implantation of the modular graft was achieved in 100% of an-
imals. Mean procedural time was 9030 Min. Mean pressure gradient between
ascending aorta and cranial vessels was 02 mmHg. All chronic animals recovered
well. Long term follow up demonstrated no graft migration or side branch occlusion/
stenosis.
Conclusions: The novel designed arch endograft (see Figure) has the potential to
provide the next evolutionary step towards an off-the-shelf, pure endovascular
solution as a ﬁrst-line intervention for major aortic arch lesions. The integrated
brachial intra-procedural latching and Brachiocephalic artery placement of a
proximal (cranial) end of the main prosthesis provides the cornerstone for
increased intra-procedural and long term endograft ﬁxation. Initial clinical work
due Q3 2014.
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Background: As ablation and transseptal procedures become more common due to
the aging population, transseptal puncture complications become a larger concern.
Iatrogenic atrial septal defects (IASDs) are typically considered to close within a year
with 7% remaining at 12 months following a puncture with a 12 Fr catheter. Today,
IASDs are also attracting attention because cryoablation and MitraClip procedures
that use larger sheaths are common. The purpose of this experimental paradigm was to
characterize the biomechanical properties of the fossa ovalis in an animal model
commonly used for testing these procedures.
Methods: The atrial septa from Yorkshire Cross swine (n¼86) were excised for
experimentation. The inferior edge of the fossa ovalis was cut off for catheter
tear testing. Samples were randomized to 3 groups, and the transseptal punctures
were performed with a: 1) standard Brockenbrough needle, 2) Baylis RF needle,
or 3) custom RF 5 Fr needle, which was unique design in this study. More
speciﬁcally, catheter tear testing allows for the investigation of the resultant ef-
fects varying catheter sizes and different transseptal approaches have on inducing
trauma.
Results: We observed that the type of needle used for the transseptal puncture
had no statistically signiﬁcant effects on tear forces (p>0.05). This suggests that
on an acute time scale, the procedure a clinician utilized to cross the septum
could be one of personal preference, since no technology demonstrated an in-
crease in tear force and thus a reduction in IASD formation. Yet, there were
signiﬁcant differences in tearing the septum between different size sheaths (p<
0.05). Noteworthy, the forces required to initiate tearing in this study were
within the range of the forces able to be generated by clinically used catheter
and sheaths.
Conclusions: Tissue properties and their role in the formation of IASDs have not been
previously well studied. This suggests a need to improve our basic understanding in
how septa tearing arise and a means to minimize damage created during procedures.
This is the one of the ﬁrst studies performed to investigate a novel transseptal
approach in an effort to minimize IASD formation.
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Background: Polymer coatings of drug eluting stents (DES) have been shown to
offer a protective barrier against acute thrombus formation compared with bare metal
stents (BMS). While this anti-thrombotic function has been assigned to contempo-
rary DES utilizing permanent polymeric coatings, the impact of bioerodible poly-
meric coatings, strut thickness and fully bioresorbable scaffolds remains to be
determined.
Methods: A porcine ex vivo carotid to jugular arterio-venous shunt model
involving a test circuit of three in-line stents, was used to test thrombogenicity.
The Synergy stent (Boston Scientiﬁc) (n¼6) was compared to 3 different
stent types: 1) BioMatrix Flex (Biosensors) 2) BVS (Abbott), and 3)
OmegaTM (Boston Scientiﬁc) (n¼6 each). After 1h of circulation, platelet
adherence in whole mount stents was identiﬁed by immunoﬂuorescent staining
against dual platelet markers (CD61/CD42b) and quantiﬁed using confocal
microscopy.
Results: Synergy DES showed the least area occupied by thrombus compared to
the other 3 stents types, with a signiﬁcant difference compared to BioMatrix Flexw Devices and Innovation B129
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comand BVS (p< 0.05)(Figure). The number of platelet aggregation clots was the
least in Synergy DES with a borderline signiﬁcant difference compared to other
stents.Conclusions: The current ex vivo swine shunt model demonstrated decreased acute
thrombogenicity in bioerodible polymer thin-strut Synergy as compared to bioerodible
thick-strut Biomatrix Flex and fully bioresorbable Absorb, which conﬁrms the acute
protective function of bioerodible stent coatings and emphasizes the relevance of stent
geometry in acute thrombogenicity.
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Background: Transcatheter paravalvular leak closure (TPVLC) has become a viable
alternative to reoperation but optimal technical strategy is still to be deﬁned. We
present a prospective TPVLC registry in which safety and efﬁcacy of multi-plug,
single-stage approach were assessed.
Methods: All subjects presented with hemodynamically signiﬁcant PVL and
symptomatic heart failure (HF). Decision on performing TPVLC was made by
the Heart Team and procedures were executed in hybrid operating room. Ante-
or retrograde access was employed for mitral while retrograde only for aortic
PVLs. 2 to 4 AVP 3 devices (size and number based on PVL channel cross-
sectional area by real-time three-dimensional transesophageal echocardiogra-
phy) were simultaneously implanted into a single PVL channel. Endpoints
were deﬁned according to VARC-2 and modiﬁed if demanded by TPVLC
speciﬁcity.
Results: Enrollment started in 2010 and reported data is complete as of December
2013. From 64 referred patients 49, with either mechanical valves (n¼30) or
stented bioprostheses, were found eligible for TPVLC. PVL location was mitral
(n¼29) or aortic. In the aortic group acute procedural success (APS) ratio was
100% and no MACCEs occurred. In the mitral group, TPVLC was successful on
ﬁrst attempt in 22 cases (4/4 in transapical and 18/25 in transseptal access).
Following transseptal failure another transapical procedure was performed in 5
patients. TPVLC ultimately proved efﬁcient in 89.7% of mitral PVLs with APS
of 76.5%. Cumulatively, TPVLC was accomplished in 46 subjects (93.9%) with
APS of 78%. When successful, it led to signiﬁcant decrease of NT-proBNP
concentration and HF symptoms regression. Safety endpoints were met in 4 pa-
tients and included non-disabling stroke (transient aphasia), plug embolization
(successfully snared) and 2 access site-related complications. In device failure
group 2 deaths occurred (end-stage HF) and 2 other patients were rehospitalized
(decompensated HF).
Conclusions: Multi-plug, single-stage TPVLC with use of AVP III devices is
effective and safe strategy in patients with hemodynamically signiﬁcant PVL. It ap-
pears exceptionally well suited for aortic PVLs.B130 JACC Vol 64/11/Suppl B jTCT-444
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Background: Transduction efﬁcacy, delivery approaches and vector serotypes are
representing major challenges for future cardiac gene therapy. The aim of this current
study was to test not only the anterograde coronary approach for gene delivery but
three different AAV serotypes (6, 7 and 9) in a pre-clinical large animal model.
Methods: The approach was tested in 19 chronically instrumented dogs which
received the AAV vectors anterograde intracoronarily. The left main coronary artery
was cannulated with a Cobra1 catheter (5F) and a micro-infusion catheter (2.5F) was
selectively advanced into LAD and RCX. The solution for infusion was prepared with
normal saline, 1x10
ˇ
13 AAV-(6, 7 or 9)-eGFP particles, SubstanceP (0.25-0.5ng/kg/
min) and Adenosine (0.15mg/kg/min) and was injected slowly over 20min. Nitro-
glycerine was given i.v. (1mg/kg/min) to further enhance endothelial penetration of the
virus. The coronary sinus was approached with a custom made balloon in eleven
subjects. Hemodynamic data were recorded and infection efﬁcacy was assessed using
immunohistochemistry for eGFP after 30days.
Results: Procedure time was signiﬁcantly longer in the cases with coronary sinus
occlusion (6010 vs. 9045min, p< 0.05). Mean arterial pressure and dP/dtmax
dropped in all cases due to the vasodilators (11815 to 5321mmHg and
2289466 to 1421414mmHg/sec). These effects were enhanced with coronary
sinus blockage that infusion had to be discontinued several times due to hypo-
tension. The eGFP-transduction rate with AAV9 was heterogeneous within the
myocardial layers (0.3-56%), with a higher transduction in the subendocardial
layer (22-45%).There was no signiﬁcant increase of eGFP-expression caused by
the additional coronary sinus blockage (p¼0.07). Comparing the different sero-
types AAV7 and AAV9 have been more effective infecting LV tissue than AAV6
(167%, 219% vs. 42%, p< 0.05).
Conclusions: Anterograde cardiac gene delivery is feasible and comparatively
effective. The addition of coronary sinus blockage did not increase efﬁciency
signiﬁcantly. Individual characteristics need to be taken into account selecting the
optimal AAV serotype for translatable results.
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Background: The deployment of the stent sometimes associates with difﬁculty
because of the unfavorable lesion characteristics including severe calciﬁcation or
tortious conﬁguration of the vessel, and insufﬁcient backup support of the guiding
catheter. To address this issue, the small-sized straight inner catheter have been
developed to access the lesion, where the stent to be implanted. Recently, a novel
4.5-Fr child catheter with hyper lubricity in outer surface to ease advancement of the
catheter was developed to improve the success rate in stent delivery.
Methods: We retrospectively evaluated 51 consecutive patients, who underwent
primary percutaneous coronary intervention with CoKatte catheter (Asahi Intecc
Co.,Ltd, Seto, Japan) after failure in delivering the stents with conventional procedure
with 6-Fr guiding catheter between January 2011 and December 2013. CoKatte
catheter is a straight catheter with 1.5mm in outer diameter, 120 cm in length, and
compatible for 6-Fr guide catheter.
Results: The mean age of the patients was 75.3 years old and 29 male patients were
included. Target vessels were comprised of 13 LADs, 7 LCXs, 27 RCAs, and 4 SVGs.
Trans-radial approach was performed in 41 patients. Six lesions were chronic total
occlusion. Seven lesions required the lesion preparation with Rotablator (Boston
Scientiﬁc Corp.) before stent delivery. For advancement and subsequent deep intu-
bation of the catheter, anchor balloon technique was needed in 42 patients, otherwise,
the catheter could be advanced under support of the guide wire or the shaft of the
balloon catheter. In all cases, stent delivery in the intended lesion was achieved. The
complication related to deep insertion of the catheter including proximal dissection, air
embolism, and severe ischemia were not observed.
Conclusions: This novel 4.5-Fr catheter is considered to contribute for facilitating
stent delivery in the complex lesion in the coronary arteries.September 13–17, 2014 j TCT Abstracts/New Devices and Innovation
